The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Site Privacy | Accessibility | Privacy Program | Copyrights | Vulnerability Disclosure | No Fear Act Policy | FOIA | Environmental Policy | Scientific Integrity | Information Quality Standards | Commerce.gov | Science.gov | USA.gov

Copyright © 2022. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Ghost is a Node.js CMS. An unused endpoint added during the development of 4.0.0 has left sites vulnerable to untrusted users gaining access to Ghost Admin. Attackers can gain access by getting logged in users to click a link containing malicious code. Users do not need to enter credentials and may not know they've visited a malicious site. Ghost(Pro) has already been patched. We can find no evidence that the issue was exploited on Ghost(Pro) prior to the patch being added. Self-hosters are impacted if running Ghost a version between 4.0.0 and 4.3.2. Immediate action should be taken to secure your site. The issue has been fixed in 4.3.3, all 4.x sites should upgrade as soon as possible. As the endpoint is unused, the patch simply removes it. As a workaround blocking access to /ghost/preview can also mitigate the issue.

Conclusion: These are the first multicentric data on the surgical concept of TMMR and tLNE for the treatment of cervical cancer FIGO IB-IIA. We were able to reproduce the excellent oncologic data described for the method albeit with a relatively short median observation time. A randomized controlled trial seems warranted to definitely establish TMMR+tLNE as the method of choice for the treatment of early cervical cancer.

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Objective: The surgical concept of total mesometrial resection (TMMR) and therapeutic lymphadenectomy (tLNE) for the treatment of early cervical cancer is based on the ontogenetic cancer field model. Unicentric data show excellent locoregional control rates without adjuvant chemoradiation. However, there are so far no prospective, multicentric data supporting the method.

Methods: The multicentric TMMR register study was designed to answer the question whether the concept of TMMR+tLNE could be transferred to different centers and surgeons without compromising the outstanding oncologic results described in a unicentric setting.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

This vulnerability has been modified since it was last analyzed by the NVD. It is awaiting reanalysis which may result in further changes to the information provided.

Secure .gov websites use HTTPS A lock () or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

By selecting these links, you will be leaving NIST webspace. We have provided these links to other web sites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other web sites that are more appropriate for your purpose. NIST does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, NIST does not endorse any commercial products that may be mentioned on these sites. Please address comments about this page to nvd@nist.gov.

Results: In 116 patients with cervical cancer stages IB-IIA, (International Federation of Gynecology and Obstetrics [FIGO] 2018), who underwent TMMR/tLNE, 25.0% were lymph node-positive. pT stages were pT1a in 3 patients (2.6%), pT1b1 in 82 (70.7%), pT1b2 in 18 (15.5%), pT2a in 4 (3.5%) and pT2b in 9 (7.8%). The overall recurrence rate was 7.8% in a median follow-up time of 24 months (6-80). Locoregional recurrences occurred in 6.0% of patients. One patient (0.9%) died from the disease during the observation period.